Form 4: Bioventus Inc. SVP & CFO Mark Singleton Acquires 31,000 Shares Through RSU Vesting

Bioventus Inc.'s SVP & CFO, Mark Singleton, acquired 31,000 shares of Class A Common Stock through the vesting of restricted stock units.

Summary

• Mark Singleton, the SVP & CFO of Bioventus Inc., acquired 31,000 shares of Class A Common Stock on December 20, 2024.
• The acquisition was a result of the vesting of restricted stock units (RSUs).
• These RSUs vested 50% on the twelve-month anniversary of the grant date and the remaining 50% on the eighteen-month anniversary, contingent on continued service.
• Following the transaction, Mr. Singleton directly owns 115,895 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation. It is a positive sign of continued service and alignment of interests, but not a major event that would significantly impact the company's outlook.

Positives

• The vesting of RSUs indicates that Mr. Singleton has met the service requirements, suggesting continued commitment to the company.
• The increase in direct ownership aligns the executive's interests with those of the shareholders.

Industry Context

This is a standard transaction for executives who receive equity compensation as part of their overall package. It is common for companies to use RSUs to align management's interests with the long-term performance of the company.

Comparison to Industry Standards

• The use of RSUs for executive compensation is a common practice across various industries, including the medical device sector where Bioventus operates.
• Companies like Stryker, Medtronic, and Zimmer Biomet also utilize similar equity-based compensation plans for their executives.
• The vesting schedule of 12 and 18 months is also fairly standard, designed to incentivize long-term commitment and performance.

Stakeholder Impact

• The transaction increases the alignment of interests between the executive and shareholders.
• The vesting of RSUs is a standard part of executive compensation and does not have a direct impact on other stakeholders.

Key Dates

Keywords

Bioventus Inc., Mark Singleton, RSU, Restricted Stock Units, Class A Common Stock, Vesting, SEC Form 4, Insider Trading